Lipella Pharmaceuticals Inc. Common Stock (LIPO) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.00 (+0.00%), Market cap $0.00B, 52-week low–high $0.02 ~ $3.09.
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh,
Financial statements, price targets, institutional (13F) holdings and related news for Lipella Pharmaceuticals Inc. Common Stock are updated in real time on BlackAll Trade.
Lipella Pharmaceuticals Inc. Common Stock trades at $0.00 (+0.00%). Real-time quotes and charts are available on BlackAll Trade.
Lipella Pharmaceuticals Inc. Common Stock has a market cap of about $0.00B.
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for v